Table 2.
Frequency of metabolic risk factors in psoriatic patients and control group
| Parameters | Psoriatic patients n = 41 |
Control group n = 41 |
χ 2 | p values | ||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| WC (≥102 cm) | 27 | 65.9 | 21 | 51.2 | 1.26 | 0.262 |
| SBP/DBP (≥130/85 mmHg) | 17 | 41.5 | 7 | 17.1 | 4.77 | 0.029 |
| Triglycerides (≥150 mg/dl) | 17 | 41.5 | 16 | 39.0 | 0.00 | 1.000 |
| HDL cholesterol (≤40 mg/dl) | 16 | 39.0 | 10 | 24.4 | 1.41 | 0.235 |
| Fasting glucose (≥100 mg/dl) | 26 | 63.4 | 13 | 31.7 | 7.04 | 0.008 |
| MetS diagnosis | 17 | 41.1 | 9 | 22.0 | 2.76 | 0.097 |
The psoriatic patients exhibited statistically significant differences compared with controls for systolic and diastolic blood pressure and fasting glucose. According to the NCEP ATP III definition, the metabolic syndrome is defined as the coexistence of three or more of the following findings: (1) Increased waist circumference. (2) Hypertriglyceridaemia. (3) Hypertension. (4) Elevated fasting plasma glucose. (5) Low high-density lipoprotein (HDL) cholesterol level. Results are expressed as number and percentage. The Chi square (χ 2) test was used to test the significance of differences between the two groups. Italicized p-values represent significant differences at p < 0.05
WC Waist Circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HDL High-density lipoprotein, MetS Metabolic Syndrome